RxDoctor Payments Data

David Brister, MD

Family Medicine · Amarillo, TXNPI 1568409589

Payments from drug & device makers

$9,327in general payments, 2019–2025

Across 342 payments — averaging $27.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • AstraZeneca$1K
  • AbbVie$922
  • Johnson & Johnson$897
  • GSK$733
  • Otsuka America Pharmaceutical, Inc.$467
  • plus $4K from 37 others

What the payments were for

  • Food & beverage$9,327100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,327 in reported general payments places this provider in the 90th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$212,954
Medicare patients
440
Services billed
6,492

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin127$132,479
EntrestoSacubitril/Valsartan59$60,020
OzempicSemaglutide37$55,276
Soliqua 100-33Insulin Glargine/Lixisenatide43$49,175
EliquisApixaban40$39,818
JanuviaSitagliptin Phosphate34$39,352
FarxigaDapagliflozin Propanediol40$37,716
MounjaroTirzepatide31$36,375
XareltoRivaroxaban29$24,112
Trelegy ElliptaFluticasone/Umeclidin/Vilanter18$19,184
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog21$17,832
MyrbetriqMirabegron19$10,806
LinzessLinaclotide13$10,724
PremarinEstrogens, Conjugated12$6,738
Spiriva RespimatTiotropium Bromide11$6,668

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Spiriva Respimat, Trijardy Xr$430$142,831150 claims
NovartisEntresto$80$60,02059 claims
Novo NordiskOzempic$1,394$55,27637 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$143$49,17543 claims
PfizerEliquis, Premarin$379$46,55652 claims
MerckJanuvia$92$39,35234 claims
AstraZenecaFarxiga$1,197$37,71640 claims
Lilly USA, LLCMounjaro$262$36,37531 claims
Johnson & JohnsonXarelto$897$24,11229 claims
GSKTrelegy Ellipta, Incruse Ellipta$733$23,30930 claims
Astellas Pharma US IncMyrbetriq$337$10,80619 claims
AbbVieLinzess$922$10,72413 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Amarillo

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →